Positive hepatitis C virus antibody in cases with history of intravenous drug abuse via community announcement: A useful experience

Journal of Isfahan Medical School

Volumn 28, Issue SPEC. ISSUE, 2011, Pages

  Nobari, Reza Fadaei ^a   Meshkati, Marjan ^a   Ataei, Behrooz ^a   Heidari, Kamal ^a   Kassaian, Nazila ^a   Nokhodian, Zari ^a   Shoaei, Parisa ^a   Yaran, Majid ^a   Adibi, Peyman ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Announcement; Community; Hepatitis C; Intravenous drug using

Indexed keywords

HEPATITIS C ANTIBODY;

ANTIBODY DETECTION; ARTICLE; COMMUNITY PROGRAM; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EDUCATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; NONHUMAN; PHYSICIAN; PILOT STUDY; PREVALENCE; PROPAGANDA; VIRUS DETECTION; VOLUNTEER;

EID: 82255161818     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Des J, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med 2008; 70(5): 606-11.
2. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav 2008; 12(4 Suppl): S7-12.
3. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41-6.
4. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005; 6(2): 159-65.
5. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26(3 Suppl 1): 2S-10S.
6. Farzanegan H. The prevalence of HBs Ag, HBs Ab and HBs Ab in Healthy blood donor and high risk group in Iran. Sang 1979; 173-82.
7. Mirahmadizadeh AR, Kadivar MR, Hemmati AR, Javadi A. Infection with HIV and hepatitis C and B viruses among injecting drug users in Shiraz, Southern Iran. International Conference on AIDS 2004; 15(11): 16.
8. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18(5): 359-63.
9. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006; 3:26.
10. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect 2005; 133(1): 127-36.
11. Navarro VJ, St Louis TE, Bell BP. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. J Clin Gastroenterol 2003; 36(5): 431-5.
12. Fuglsang T, Fouchard JR, Ege PP. [Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen]. Ugeskr Laeger 2000; 162(27): 3860-4.
13. Gjeruldsen SR, Myrvang B, Opjordsmoen S. A 25-year follow-up study of drug addicts hospitalized for acute hepatitis: present and past morbidity. Eur Addict Res 2003; 9(2): 80-6.